(19)
(11) EP 1 362 601 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
28.02.2007 Bulletin 2007/09

(45) Mention of the grant of the patent:
03.01.2007 Bulletin 2007/01

(21) Application number: 02700679.0

(22) Date of filing: 21.02.2002
(51) International Patent Classification (IPC): 
G01N 33/50(2006.01)
(86) International application number:
PCT/JP2002/001562
(87) International publication number:
WO 2002/066073 (29.08.2002 Gazette 2002/35)

(54)

METHOD OF EXAMINING EFFECT OF ANGIONEGESIS INHIBITOR MEDIATED BY THE INHIBITION OF INTEGRIN EXPRESSION

VERFAHREN ZUR UNTERSUCHUNG DER WIRKUNG EINES ANGIONEGESIS-HEMMERS UNTER VERMITTLUNG DURCH HEMMUNG DER INTEGRIN-EXPRESSION

PROCEDE SERVANT A ANALYSER L'EFFET D'UN INHIBITEUR D'ANGIOGENESE MEDIE PAR L'INHIBITION DE L'EXPRESSION DE L'INTEGRINE

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

(30) Priority: 21.02.2001 JP 2001044646

(43) Date of publication of application:
19.11.2003 Bulletin 2003/47

(60) Divisional application:
06013455.8 / 1742052

(73) Proprietor: Eisai Co. Ltd
Tokyo 112-8088 (JP)

(72) Inventors:
  • ONO, Naoto, c/o Eisa Co. Ltd, Tsukuba Res. Lab.
    Tsukuba-shi, Ibaraki 300-2635 (JP)
  • SENBA, Taro, c/o Eisai Co. Ltd, Tsukuba Res. Lab.
    Tsukuba-shi, Ibaraki 300-2635 (JP)
  • HATA, Naoko, c/o Eisai Co. Ltd., Tsukuba Res. Lab
    Tsukuba-shi, Ibaraki 305-2635 (JP)
  • FUNAHASHI, Yasuhiro, c/o Eisai Co. Ltd,
    Tsukuba-shi, Ibaraki 300-2635 (JP)
  • WAKABAYASHI, Toshiaki, c/o Eisai Co. Ltd.
    Tsukuba-shi, Ibaraki 300-2635 (JP)

(74) Representative: Dean, John Paul et al
Withers & Rogers LLP Goldings House, 2 Hays Lane
London SE1 2HW
London SE1 2HW (GB)


(56) References cited: : 
WO-A-00/41469
WO-A1-00/50395
WO-A1-95/07276
US-A- 5 843 906
 WO-A-98/44797
WO-A1-01/56607
WO-A1-99/02551
   
  • TRIKHA MOHIT ET AL: "Human prostate carcinoma cells express functional alpha-IIb-beta-3 integrin" CANCER RESEARCH, vol. 56, no. 21, 1996, pages 5071-5078, XP002326754 ISSN: 0008-5472
  • VERHEUL HENK M W ET AL: "Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets" BLOOD, vol. 96, no. 13, 15 December 2000 (2000-12-15), pages 4216-4221, XP002327392 ISSN: 0006-4971
  • VERHEUL H M ET AL: "Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas." CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. JAN 2000, vol. 6, no. 1, January 2000 (2000-01), pages 166-171, XP002327393 ISSN: 1078-0432
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).